Zoetis Inc.
ZTSNew York Stock ExchangeFull coverage
Latest dossier
AI-generated
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers
Q3 of fiscal year 2026 · Published Nov 9, 2026,
Zoetis is the largest animal-health company by revenue, selling prescription medicines, vaccines and diagnostics for pets and farm animals, mostly through veterinarians. Its core pet franchises are losing price and share for the first time: in the third quarter of 2026 dermatology revenue fell 15.7% as cheaper rival drugs arrived, US companion-animal revenue fell 8%, and adjusted EPS rose only because the share count was 7.1% lower. Livestock and diagnostics are still growing, and management expects US approval of long-acting Cytopoint and Simparica Duo by the end of 2026, but says it will not plan for any improvement in competition in 2027. Moatsight estimates revenue of about $9.2 billion and free cash flow of about $2.25 billion over the next four quarters.
What you pay
| Figure | At the close | 5-yr median | 5-yr range |
|---|---|---|---|
| P/E | No value: no close yet | No value: no price history | |
| EV/Sales | No value: no close yet | No value: no price history | |
| EV/EBITDA | No value: no close yet | No value: no price history | |
| Price/FCF | No value: no close yet | No value: no price history | |
| Market cap | No value: no close yet | ||
| Net debt and other claims(enterprise value minus market cap) | No value: no close yet | ||
| Enterprise value | No value: no close yet |
How the business is doing
| Figure | Last 12 months | 1-year change1-year | Yearly, 3 years | 8 quarters |
|---|---|---|---|---|
| Revenue | No value: cannot be derived | No value: cannot be derived | No value: cannot be derived | Each quarter is listed in the row's details. |
| Diluted EPS | No value: cannot be derived | No value: cannot be derived | No value: cannot be derived | Each quarter is listed in the row's details. |
| Free cash flow | No value: cannot be derived | No value: cannot be derived | No value: cannot be derived | Each quarter is listed in the row's details. |
| Gross margin | No value: cannot be derived | No value: cannot be derived | No value: cannot be derived | Each quarter is listed in the row's details. |
| Operating margin | No value: cannot be derived | No value: cannot be derived | No value: cannot be derived | No value: cannot be derived |
| Net margin | No value: cannot be derived | No value: cannot be derived | No value: cannot be derived | Each quarter is listed in the row's details. |
| Share count | 411.600M | −7.1%(better for the company) | −3.7% | Each quarter is listed in the row's details. |
How to read these figures
- Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
- 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
- Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
- 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
- n/m: not meaningful, such as a rate of change from a loss.
- Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.
Price
No closing prices are stored for this listing yet.
Facts
- Exchange
- New York Stock Exchange · USD
- Kind
- Common stock
- Security
- Common Stock